SG169358A1 - Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base - Google Patents

Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

Info

Publication number
SG169358A1
SG169358A1 SG201100648-3A SG2011006483A SG169358A1 SG 169358 A1 SG169358 A1 SG 169358A1 SG 2011006483 A SG2011006483 A SG 2011006483A SG 169358 A1 SG169358 A1 SG 169358A1
Authority
SG
Singapore
Prior art keywords
escitalopram
base
salts
crystalline
oxalate
Prior art date
Application number
SG201100648-3A
Other languages
English (en)
Inventor
Robert Dancer
Hans Petersen
Ole Nielsen
Michael Harold Rock
Helle Eliasen
Ken Liljegren
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG169358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SG169358A1 publication Critical patent/SG169358A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201100648-3A 2005-06-22 2006-06-22 Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base SG169358A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500912 2005-06-22

Publications (1)

Publication Number Publication Date
SG169358A1 true SG169358A1 (en) 2011-03-30

Family

ID=37546630

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201100648-3A SG169358A1 (en) 2005-06-22 2006-06-22 Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

Country Status (39)

Country Link
EP (3) EP2325177A1 (enExample)
JP (5) JP4906852B2 (enExample)
KR (5) KR101340815B1 (enExample)
CN (2) CN101928269A (enExample)
AR (2) AR055062A1 (enExample)
AT (3) AT10983U1 (enExample)
AU (2) AU2006261452B2 (enExample)
BG (1) BG66086B1 (enExample)
BR (1) BRPI0612295A2 (enExample)
CA (2) CA2612827C (enExample)
CY (1) CY1112392T1 (enExample)
CZ (3) CZ301286B6 (enExample)
DE (2) DE112006001619T5 (enExample)
DK (3) DK1896439T4 (enExample)
EA (2) EA201001108A1 (enExample)
EE (1) EE00773U1 (enExample)
ES (2) ES2356838T5 (enExample)
FI (2) FI20080548L (enExample)
GB (2) GB2448834B (enExample)
HR (1) HRP20110093T4 (enExample)
HU (1) HUP0800135A3 (enExample)
IL (1) IL187454A0 (enExample)
IS (1) IS8705A (enExample)
LT (1) LT5550B (enExample)
LV (1) LV13677B (enExample)
MX (1) MX2007015328A (enExample)
MY (2) MY143239A (enExample)
NO (2) NO20080359L (enExample)
PL (2) PL1896439T5 (enExample)
PT (1) PT1896439E (enExample)
RS (1) RS51575B2 (enExample)
SG (1) SG169358A1 (enExample)
SI (1) SI1896439T2 (enExample)
SK (1) SK500402007A3 (enExample)
TR (2) TR200708792T1 (enExample)
TW (2) TWI358407B (enExample)
UA (1) UA86536C2 (enExample)
WO (1) WO2006136169A2 (enExample)
ZA (2) ZA200711066B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
WO2008104880A2 (en) * 2007-03-01 2008-09-04 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
SI2595979T1 (sl) 2010-07-23 2016-09-30 H. Lundbeck A/S Proces za čiščenje farmacevtsko sprejemljivih soli Escitaloprama
CN103360353A (zh) * 2013-08-07 2013-10-23 中国药科大学 草酸艾司西酞普兰杂质的制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) * 2017-04-10 2018-10-18 東和薬品株式会社 エスシタロプラム医薬組成物
CN110711198B (zh) * 2018-07-12 2022-03-15 山东大学 D-甘露糖在制备抗抑郁药物中的应用
KR102331187B1 (ko) 2019-04-09 2021-11-26 주식회사 라이트팜텍 에스시탈로프람을 함유하는 안정성이 우수한 경구용 액제 조성물 및 그의 제조방법
US20240100012A1 (en) * 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
JPH05222041A (ja) * 1992-02-13 1993-08-31 Mitsubishi Gas Chem Co Inc アデニン誘導体の精製法
HUT74514A (en) * 1994-01-27 1997-01-28 Janssen Pharmaceutica Nv Rapidly dissolving oral dosage form
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
EP0993524B1 (en) 1997-06-30 2002-11-20 Beloit Technologies, Inc. Method and apparatus for the high speed application of coating to a traveling paper web
JP3526581B2 (ja) 1997-07-08 2004-05-17 ハー・ルンドベック・アクティーゼルスカブ シタロプラムの製造方法
CN1286687A (zh) 1997-11-11 2001-03-07 H·隆德贝克有限公司 制备西酞普兰的方法
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
CN1469737A (zh) * 2000-10-16 2004-01-21 ��һ��������ҩ��ʽ���� 口腔内快速崩解的药用组合物及其制备方法
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
TR200201166T1 (tr) * 2000-12-22 2002-10-21 H.Lundbecks A/S Saf sitalopram hazırlanması için yöntem
JP2003519121A (ja) * 2000-12-28 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット 純粋なシタロプラムの製造方法
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
GB0113842D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
ATE352546T1 (de) * 2001-07-31 2007-02-15 Lundbeck & Co As H Kristalline zusammensetzung enthaltend escitalopram
IS7239A (is) 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
WO2003092659A1 (en) * 2002-05-03 2003-11-13 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
NZ540281A (en) 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
CN1510024A (zh) * 2002-12-24 2004-07-07 北京德众万全药物技术开发有限公司 可用于制备西酞普兰(s)-对映异构体的新的化合物及其制备方法
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
JP4739217B2 (ja) * 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
IN234086B (enExample) * 2003-10-15 2009-05-29 Fuji Chem Ind Co Ltd
AU2003282383A1 (en) * 2003-11-20 2005-06-08 Natco Pharma Limited A process for the preparation of high purity escitalopram
HU227491B1 (en) * 2003-11-25 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Tablet containing citalopram hydrogen bromide
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
EP1877394A1 (en) * 2005-04-04 2008-01-16 Jubilant Organosys Limited Process for the preparation of escitalopram or its acid addition salts

Also Published As

Publication number Publication date
PT1896439E (pt) 2011-02-15
HRP20110093T1 (hr) 2011-03-31
AU2010200844A1 (en) 2010-04-01
JP4415056B2 (ja) 2010-02-17
LV13677B (en) 2008-05-20
EP1896439B1 (en) 2011-02-02
JP5731957B2 (ja) 2015-06-10
MX2007015328A (es) 2008-02-15
SI1896439T2 (sl) 2014-12-31
TR201000625T1 (tr) 2010-03-22
EA019239B1 (ru) 2014-02-28
CN101189220A (zh) 2008-05-28
DE602006019961D1 (de) 2011-03-17
FI20080548A7 (fi) 2008-10-07
AU2006261452B2 (en) 2010-02-04
TR200708792T1 (tr) 2008-05-21
AR079750A2 (es) 2012-02-15
CN101928269A (zh) 2010-12-29
ES2356838T3 (es) 2011-04-13
EP2325177A1 (en) 2011-05-25
MY143239A (en) 2011-04-15
KR20110084341A (ko) 2011-07-21
AU2006261452A1 (en) 2006-12-28
CA2612827C (en) 2010-11-30
BG66086B1 (bg) 2011-03-31
JP2008546724A (ja) 2008-12-25
ES2319073B1 (es) 2010-02-26
CA2612827A1 (en) 2006-12-28
UA86536C2 (ru) 2009-04-27
ZA200901698B (en) 2010-04-28
GB2448834A (en) 2008-10-29
CZ299906B6 (cs) 2008-12-29
DK200800075A (da) 2008-03-15
KR20120064140A (ko) 2012-06-18
PL1896439T3 (pl) 2011-04-29
EP1896439A2 (en) 2008-03-12
JP2012072168A (ja) 2012-04-12
AT10983U1 (de) 2010-02-15
EA201001108A1 (ru) 2011-02-28
GB2442160A (en) 2008-03-26
TWI358407B (en) 2012-02-21
SK500402007A3 (sk) 2008-05-06
DK200900284A (da) 2009-02-27
CZ2007898A3 (cs) 2008-01-23
AR055062A1 (es) 2007-08-01
NO20101777L (no) 2008-01-18
EA200800102A1 (ru) 2008-04-28
SI1896439T1 (sl) 2011-03-31
FI20077133A7 (fi) 2007-12-20
WO2006136169A2 (en) 2006-12-28
RS51575B (sr) 2011-08-31
GB2448834B (en) 2010-01-20
KR20100133023A (ko) 2010-12-20
RS51575B2 (sr) 2018-02-28
GB0724557D0 (en) 2008-01-23
AT11883U1 (de) 2011-06-15
CA2646780A1 (en) 2006-12-28
TW200740785A (en) 2007-11-01
FI20077133L (fi) 2007-12-20
DK1896439T4 (en) 2015-01-12
TW201130808A (en) 2011-09-16
FI20080548L (fi) 2008-10-07
KR20080018191A (ko) 2008-02-27
HUP0800135A2 (en) 2008-06-30
CY1112392T1 (el) 2015-12-09
EE00773U1 (et) 2008-10-15
ES2319073A1 (es) 2009-05-01
TWI347942B (en) 2011-09-01
MY143252A (en) 2011-04-15
LT2008005A (en) 2008-10-27
HRP20110093T4 (hr) 2015-02-27
BG110024A (bg) 2008-05-30
LT5550B (lt) 2009-03-25
GB0811164D0 (en) 2008-07-23
CZ300686B6 (cs) 2009-07-15
GB2442160B (en) 2010-01-20
EP1896439B2 (en) 2014-10-15
PL1896439T5 (pl) 2016-01-29
IS8705A (is) 2008-01-14
JP2009046506A (ja) 2009-03-05
DK1896439T3 (da) 2011-02-28
ZA200711066B (en) 2009-07-29
NO20080359L (no) 2008-01-18
IL187454A0 (en) 2008-02-09
CZ301286B6 (cs) 2009-12-30
DE112006001619T5 (de) 2008-06-12
WO2006136169A3 (en) 2007-10-18
KR20110033310A (ko) 2011-03-30
JP2009179635A (ja) 2009-08-13
PL384185A1 (pl) 2008-06-23
ES2356838T5 (es) 2015-01-26
EP2385044A1 (en) 2011-11-09
HUP0800135A3 (en) 2009-01-28
JP4906852B2 (ja) 2012-03-28
KR101340815B1 (ko) 2013-12-11
BRPI0612295A2 (pt) 2011-01-04
JP2009179634A (ja) 2009-08-13
ATE497500T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
LT2008005A (en) Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
CA2360287A1 (en) Crystalline base of citalopram
ES2195554T3 (es) Metodo para la preparacion de citalopram.
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
WO2007124757A3 (en) Use of escitalopram for improving cognition
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
SI1506185T1 (sl) Spojine in njihova uporaba kot inhibitorji 5-HT
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
CO5390076A1 (es) Composiciones farmaceuticas
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
WO2023178111A3 (en) Organic compounds
WO2005058890A3 (en) Hydronopol derivatives as agonists on human orl1 receptors
MY143987A (en) Constrained himbacine analogs as thrombin receptor antagonists
WO2006060681A3 (en) Pharmaceutical composition containing an anti-nucleating agent
WO2006123243A3 (en) Pharmaceutical dosage forms comprising escitalopram in form of granules
RU2008102238A (ru) Таблетка, содержащая труднорастворимый активный ингредиент
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
WO2005051349A3 (en) Pharmaceutical compositions of mirtazapine
TH98476B (th) เบสที่เป็นผลึกของเอสซิทาโลแปรม และยาเม็ดกระจายตัวในปากซึ่งประกอบรวมด้วยเอสซิทาโลแปรมเบส
JP2007533705A5 (enExample)
UA89656C2 (ru) Фармацевтическая композиция, которая диспергируется перорально, и способ ее приготовления
WO2005049024A3 (de) Feste pharmazeutische zubereitungsform
UA88284C2 (ru) Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения
RU2003115326A (ru) Способ коррекции гиперагрегационного эффекта комбинированных эстроген-гестагенов при лечении ювенильных маточных кровотечений
HK1067047A (en) The use of enantiomeric pure escitalopram